This site is intended for US healthcare providers only.          FOR PATIENTS
Resources 2017-07-27T10:01:46-04:00

Resources

Get the latest about ORALAIR and allergy treatment information—from in-office materials to help facilitate conversation with patients to deciding on a fulfillment option, you will find everything you need right here.

Allergy Perspectives
HCP Resources
Fulfillment Resources
Patient Resources

Join
ALLERGY PERSPECTIVES
and receive allergy treatment information and resources

Join
ALLERGY PERSPECTIVES
and receive allergy treatment information and resources

SIGN UP TODAY

to receive your Allergy Immunotherapy Compendium: a comprehensive reference designed to help you diagnose and treat allergic disorders.
SIGN UP TODAY

By becoming a member, you will receive communications representing the perspectives of your peers, patients, and our experts, as well as helpful resources and tools.

Some important materials you will have access to include

  • Educational Materials

  • Clinical Resources

  • The Stallergenes Greer Service Team (an Allergy Account Specialist, a Customer Care Specialist, and our Medical and Scientific Affairs Team)

Learn more about ORALAIR and allergy immunotherapy

With resources delivered by a sales representative, or available as a PDF.

Allergy Immunotherapy Primer

An introduction to allergy immunotherapy (AIT). This brochure covers efficacy, safety, and tips for discussing AIT with patients.

Download Now

ORALAIR® Leave Behind

For an in-depth look at ORALAIR, request a sales representative, and one of our team members will walk you through the piece answering any questions you may have.

Request

ORALAIR® Dosing Card

This compact piece contains all of the information you will need for dosing and administration, and can be conveniently stored in your office for quick reference when with a patient.

Request

Deciding on a fulfillment option?

Make sure that you find the best plan for you and your patients.

Fulfillment Detail Aid

Get a detailed outline of every fulfillment option that may be available to you for ORALAIR®. This brochure covers the differences between using a retail or specialty pharmacy, as well as the benefits of ePrescribing.

Request

Specialty Pharmacy Enrollment Form

If you decide to use a specialty pharmacy, you’ll need to download and fill out this enrollment form.

Download Now

Patient Fulfillment Tear Pad

Outlines the two paths to fulfillment, at-home delivery and in-store pickup, so that patients can choose the option that best fits their needs.

Request

Be prepared to discuss ORALAIR with your patients

Ease patients into the conversation with these resources.

Patient AIT Primer

Give patients the opportunity to learn more about allergy immunotherapy, and what to expect when being treated with immunotherapy.

Request

Patient Initiation Brochure

For patients who are new to ORALAIR, this brochure covers benefits, risks, and administration so they know what to expect when starting ORALAIR.

Download Now

In-Office Poster

Hang this ORALAIR poster in your office to help educate your grass allergy patients about the benefits of an allergy immunotherapy option.

Request
Back to top

Initiate treatment with ORALAIR 4 months before the expected onset of each grass pollen season and maintain it throughout the grass pollen season.1

Indications and Usage

ORALAIR is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for any of the 5 grass species contained in this product. ORALAIR is approved for use in persons 5 through 65 years of age.

ORALAIR is not indicated for the immediate relief of allergy symptoms.

Important Safety Information

WARNING: SEVERE ALLERGIC REACTIONS

  • ORALAIR can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal edema.
  • Do not administer ORALAIR to patients with severe, unstable or uncontrolled asthma.
  • Observe patients in the office for at least 30 minutes following the initial dose.
  • Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.
  • ORALAIR may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.
  • ORALAIR may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

ORALAIR is contraindicated in patients with severe, unstable or uncontrolled asthma, patients with a history of any severe systemic allergic reaction or severe local reaction to sublingual allergen immunotherapy or of eosinophilic esophagitis, or patients who are hypersensitive to any of the inactive ingredients.

ORALAIR can cause systemic allergic reactions, including anaphylaxis, and severe local reactions, including laryngopharyngeal swelling, which may be life-threatening. Severe and serious allergic reactions may require treatment with epinephrine. Patients who have a systemic allergic reaction to ORALAIR should stop taking the product. Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy. Discontinue ORALAIR in patients with persistent symptoms of eosinophilic esophagitis, including dysphagia or chest pain. ORALAIR treatment should be withheld if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ORALAIR. Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.

In case of oral inflammation or wounds, such as following oral surgery or dental extraction, ORALAIR treatment should be discontinued to allow complete healing of the oral cavity. The risk of ORALAIR may be increased when treatment is initiated during the grass pollen season.

The most common adverse events reported in ≥5% of patients were oral pruritus, throat irritation, ear pruritus, mouth edema, tongue pruritus, cough, and oropharyngeal pain. Patients who have escalating or persistent local reactions to ORALAIR should be reevaluated and considered for discontinuation of ORALAIR.

ORALAIR should be used during pregnancy or breastfeeding only if clearly needed.

Please click here for full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

All material and content herein Copyright © 2018 Stallergenes Greer S.A. Inc. No material from this Web site may be used, reproduced, or copied in whole or in part without prior written permission from Stallergenes Greer S.A. All Rights Reserved Worldwide.
ORALAIR® is a registered trademark of Stallergenes Greer or its affiliates.
Allergy Perspectives is a registered trademark of Stallergenes Greer or its affiliates.
CoverMyMeds® is a registered trademark of CoverMyMeds LLC.
HubExpressSM is a service mark of CoverMyMeds LLC.
Stallergenes Greer Inc. 55 Cambridge Parkway, Suite 400, Cambridge, MA 02142
© Stallergenes Greer 2018. All Rights Reserved.